**Letters to the Editor**

**Mutations in POGLUT1 in Galli–Galli/Dowling–Degos disease**

DOI: 10.1111/bjd.14914

**Dear Editor,** The group of reticulate pigmentary disorders includes the rare autosomal dominant Dowling–Degos disease (DDD) and Galli–Galli disease (GGD; OMIM 179850, 615327 and 615696).1 In light of substantial clinical, histological and mutational overlap between GGD and DDD, they are considered to belong to the same entity.2,3 Mutations in KRT5 (encoding keratin 5) have been associated with GGD/DDD since 2006.2–5 With the development of whole-exome sequencing, mutations in POFUT1 (encoding protein O-fucosyltransferase 1)6,7 and POGLUT1 (encoding protein O-glucosyltransferase 1)8 have been shown to underlie some cases of GGD/DDD. We report mutations in POGLUT1 in three families of European ancestry.

In family 1 the mother presented, aged 75 years, with a 40-year history of reticulate hyperpigmented scaling plaques on the neck, lateral proximal arms, proximal legs and popliteal fossae (Fig. 1a, b). Light microscopy revealed epidermal acanthosis, hypergranulosis and hyperkeratosis with parakeratosis and suprabasilar acantholysis (Fig. 1c). Direct DNA sequencing of KRT5 was negative for mutations. A whole-exome sequencing approach was taken using DNA from the affected mother (Appendix S1 and Table S1; see Supporting Information). During this time mutations were reported in POFUT1 and POGLUT1. A previously reported heterozygous nonsense mutation was identified in POGLUT1, p.Arg218*, and confirmed by Sanger sequencing. The mutation was identified in her affected son but not in two unaffected daughters.

A second family with GGD/DDD, present in two generations, was also negative for KRT5 mutation. The proband was a 40-year-old man who progressively developed, starting from adolescence, small red-brown scaly lesions. These started on her legs then spread onto her forearms with a few lesions on her trunk (Fig. 1g–j). Her mother had similar lesions. Light microscopy of different skin biopsies variably showed focal hyperkeratosis, focal parakeratosis, acantholysis and elongation of rete ridges with a mild patchy chronic inflammatory infiltrate in the upper dermis (Fig. 1k). One biopsy showed acantholysis, (Fig. 1l). Screening of KRT5 and POGLUT1 did not yield any mutations. A heterozygous missense mutation was identified in POGLUT1, p.Cys286Tyr; c.857G>A, in both affected individuals (Fig. 2c, d). PolyPhen-2 and MutationTaster predict this previously unreported variant as disease causing; it is not in the dbSNP, NHLBI Exome Variant Server or ExAC databases. p.Cys286 is highly conserved across a number of species.

Mutations in POGLUT1 were reported by Basmanav et al.8 in 13 unrelated individuals. The majority were nonsense mutations, but there were also a splice-site and a missense mutation. We identified one previously reported nonsense mutation, p.Arg218*, and two previously unreported missense mutations, p.Gly170Glu and p.Cys286Tyr. The p.Arg218* mutation results in a truncated form of POGLUT1 that lacks part of the substrate-binding site required for high-affinity binding of UDP-glucose.8

Using homology modelling, we investigated the effects of the two missense mutations (Fig. 2e). Gly170 is on a short helical segment with C-alpha hydrogens directed into a hydrophobic pocket that likely stabilizes a subdomain, part of the N-terminal domain. This pocket is about 15 Å distant from the site of catalysis. A mutation to glutamate places a polar and acidic side chain into this hydrophobic environment. The result would be potentially destabilizing electrostatic interactions and steric clashes with Val137, Tyr161 and Ile176. Cys286 is in the C-terminal domain, close to Cys263. The model strongly suggests that a disulfide bond would be formed by these two residues. Mutation of Cys286 to tyrosine would remove the highly stabilizing disulfide bond that holds together distinct elements of secondary structure, and then, depending on which side-chain rotamers were adopted, to clash with Phe278, His282, Leu283, Val260 and Ser288, which form part of the hydrophobic core of the C-terminal

---

2. KRT5 mutations in GGD/DDD and Galli disease.
3. POGLUT1 mutations in GGD/DDD.
4. In silico prediction tools, MutationTaster (http://www.mutationtaster.org/) and PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2/), predict this to be a disease-causing variant. It is not in the dbSNP (http://www.ncbi.nlm.nih.gov/SNP/), NHLBI Exome Variant Server (http://evs.gs.washington.edu/EVS/) or ExAC (http://exac.broadinstitute.org/) databases. No mutations were identified in POFUT1.
5. A 52-year-old woman, in family 3, presented at age 50 years with a 10-year history of multiple, sometimes itchy, small red-brown scaly lesions. These started on her legs then spread onto her forearms with a few lesions on her trunk (Fig. 1g–j). Her mother had similar lesions. Light microscopy of different skin biopsies variably showed focal hyperkeratosis, focal parakeratosis, acantholysis and elongation of rete ridges with a mild patchy chronic inflammatory infiltrate in the upper dermis (Fig. 1k). One biopsy showed acantholysis, (Fig. 1l). Screening of KRT5 and POGLUT1 did not yield any mutations. A heterozygous missense mutation was identified in POGLUT1, p.Cys286Tyr; c.857G>A, in both affected individuals (Fig. 2c, d). PolyPhen-2 and MutationTaster predict this previously unreported variant as disease causing; it is not in the dbSNP, NHLBI Exome Variant Server or ExAC databases. p.Cys286 is highly conserved across a number of species.
6. Mutations in POGLUT1 were reported by Basmanav et al.8 in 13 unrelated individuals. The majority were nonsense mutations, but there were also a splice-site and a missense mutation. We identified one previously reported nonsense mutation, p.Arg218*, and two previously unreported missense mutations, p.Gly170Glu and p.Cys286Tyr. The p.Arg218* mutation results in a truncated form of POGLUT1 that lacks part of the substrate-binding site required for high-affinity binding of UDP-glucose.8
7. Using homology modelling, we investigated the effects of the two missense mutations (Fig. 2e). Gly170 is on a short helical segment with C-alpha hydrogens directed into a hydrophobic pocket that likely stabilizes a subdomain, part of the N-terminal domain. This pocket is about 15 Å distant from the site of catalysis. A mutation to glutamate places a polar and acidic side chain into this hydrophobic environment. The result would be potentially destabilizing electrostatic interactions and steric clashes with Val137, Tyr161 and Ile176. Cys286 is in the C-terminal domain, close to Cys263. The model strongly suggests that a disulfide bond would be formed by these two residues. Mutation of Cys286 to tyrosine would remove the highly stabilizing disulfide bond that holds together distinct elements of secondary structure, and then, depending on which side-chain rotamers were adopted, to clash with Phe278, His282, Leu283, Val260 and Ser288, which form part of the hydrophobic core of the C-terminal.
Fig 1. Clinical findings. (a, b) Reticulate hyperpigmented scaling plaques on the proximal legs of the proband of family 1. (c) Light microscopy of three punch biopsies from the proband of family 1 revealed similar findings of filiform digitate downgrowth of the epidermal rete ridges, presence of small horn cysts, epidermal acanthosis, hypergranulosis, and hyperkeratosis with parakeratosis and suprabasilar acantholysis. (d) Small red-brown macules and crusted papules widely distributed over the trunk, neck, back, abdomen and limbs of the proband of family 2. The large body folds, hands and feet, and face were spared. (e) The father of the proband of family 2 had similar clinical features, limited to the neck region without involvement of the large flexures. (f) Light microscopy shows some apical acantholysis and parakeratosis with a moderate dermal inflammatory infiltrate. (g–j) The proband of family 3 with multiple small (approximately 5-mm-diameter) red-brown scaly papules, present predominantly on the legs but also on the forearms with some postinflammatory change from previous lesions. (k) Light microscopy from the proband of family 3, a medium-power view showing elongation of the rete ridge and modest inflammatory infiltrate. (l) A medium-power view of a second biopsy from the right anterior thigh. There is an intraepidermal vesicle, as a result of acantholysis of the keratinocytes, some of which show dyskeratosis. Note the elongation of the rete ridges immediately below the vesicle.
Wild type POGLUT1, exon 5

Wild type POGLUT1, exon 9

POGLUT1 p.Gly170Glu

POGLUT1 p.Cys286Tyr

UDP-glucose binding site and catalytic cleft

Hydrophobic cluster Val137, Tyr161, Ile176

C-terminal domain

Cys286

Cys263

N-terminal domain
domain. Again, the consequence would be to destabilize the protein fold at a position about 15 Å from the site of catalysis. These models predict that each missense mutation, p.Gly170Glu and p.Cys286Tyr, would compromise enzyme activity due to a reduction in stability of the protein fold near the active site.

POGLUT1 adds O-linked glucose to serine residues in epidermal growth factor-like repeats of Notch receptors, and is an essential regulator of Notch signalling. Loss of Notch1 and Notch2 in mice results in abnormal pigmentation; these and other studies suggest that mutations in POGLUT1 resulting in aberrations in Notch signalling would lead to abnormal pigmentation and keratinocyte morphology.9,10

Differences were noted between our cases. In family 2, lesions were widely scattered over the entire trunk and limbs (son) and on the neck and upper trunk region (father), rather than in a reticulated pattern. Similarly, in family 3 there was no reticulate rash compared with that of family 1. With only a small number of cases reported it is difficult to draw any genotype–phenotype correlation.

These findings expand the spectrum of mutations in POGLUT1 and confirm POGLUT1 as the third candidate gene, along with KRT5 and POFUT1, to consider in diagnosis of GGD/DDD.

Acknowledgments

We thank all of the patients and families involved in this study.

1Dermatology and Genetic Medicine, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee, U.K.
2Division of Computational Biology and Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee, U.K.
4Department of Dermatology, Oregon Health & Sciences University, Portland, OR, U.S.A.
5Division of Dermatology, Dartmouth-Hitchcock Medical Center, Lebanon, NH, U.S.A.
6Department of Dermatology, University Hospital-Ingh Chespirit Bern, University of Bern, Bern, Switzerland
7Department of Dermatology and 8Department of Histopathology, Royal Hallamshire Hospital, Sheffield, U.K.
9Department of Clinical Genetics, Sheffield Children’s Hospital, Sheffield, U.K.
10Pachyonychia Congenita Project, Salt Lake City, UT, U.S.A.
Correspondence: Frances J.D. Smith. E-mail: frances.smith@pachyonychia.org

References


Supporting Information

Additional Supporting Information may be found in the online version of this article at the publisher’s website:
Appendix S1. Supplementary methods.
Regional variation of hidradenitis suppurativa in the Norwegian Patient Registry during a 5-year period may describe professional awareness of the disease, not changes in prevalence

DOI: 10.1111/bjd.14990

Dear Editor, Hidradenitis suppurativa (HS) is a distinct skin disease characterized by well-defined signs, symptoms and a notorious tendency to recurrence and chronicity. Nevertheless, considerable uncertainty exists regarding its prevalence. The prevalence has been estimated over recent decades with a significant degree of unexplained discrepancy, ranging from 0.05% to 8% in available studies. In general, registry-based studies tend to indicate lower prevalence rates than reports based on physician-examined or self-reported data. It may be suspected that registry data are influenced by local variations in the healthcare system.

We accessed the Norwegian Patient Registry, which is a public registry providing basic descriptive data on all patients treated in public hospitals, polyclinics and by practising specialists under public contract. The registry is based on International Classification of Diseases (ICD)-10 coding and allows for the comparison of registry-based prevalence estimates of different diseases for the different health regions of Norway. Therefore, it offers data generally comparable with data described in other registry studies.

We investigated possible differences in the number of patients treated for HS in various Norwegian health regions in order to explore the variation in prevalence rates. Patients were identified based on the ICD code for HS (L73.2) and simple descriptive statistics provided for each region. Data are shown in Figures 1 and 2.

Two relevant observations could be made based on the data. Firstly, the prevalence rates varied widely. The number of cases coded by specialists show large differences between the